FDA Standardizes REMS Documents For Certain Fentanyl Products
This article was originally published in The Pink Sheet Daily
Executive Summary
ProStrakan's Abstral is first use of the REMS templates; the agency expects sponsors of similar immediate-release transmucosal products to follow suit and share a REMS implementation system.